Phobia, Social: Clinical Trials

25 trials for Phobia, Social, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

25 completed. 25 Phase 3, 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 325Completed 25
Phase 26Completed 6

Follow Phobia, Social: new trials by email Literature Review of Phobia, Social trials Research Report on Phobia, Social

Trials (filtered) newest first · largest first

All 25 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety
Centanafadine, Placebo - ADHD, Anxiety
Phase 3CompletedOtsuka Pharmaceutical Development & Commercialization, Inc.3152025-03-262026-05-06
Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1
225 mg BNC210, Placebo - Social Anxiety Disorder
Phase 3CompletedBionomics Limited3702024-08-062026-05-19
PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge
PH94B Nasal Spray, Placebo Nasal Spray - Social Anxiety Disorder
Phase 3CompletedVistaGen Therapeutics, Inc.2242021-05-242025-09-12
Acute Anxiolytic Effects of Riluzole on Subjects With Social Anxiety Disorder
BHV-0223, Placebo - Social Anxiety Disorder, Performance Anxiety
Phase 2 / Phase 3CompletedYale University222017-01-012021-05-20
Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD)
PH94B, Placebo - Social Anxiety Disorder
Phase 3CompletedPherin Pharmaceuticals, Inc.232014-03-012015-12-07
Computerized Cognitive Behavioral Therapy for Childhood Anxiety in Community Health Centers
Computerized Cognitive Behavioral Therapy, Treatment as usual - Generalized Anxiety Disorder, Social Phobia
Phase 3CompletedUniversity of South Florida1002011-08-012019-06-18
Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders
Cognitive-behavioral therapy, Treatment as Usual - Autism, Asperger's Syndrome
Phase 2 / Phase 3CompletedUniversity of South Florida452010-04-012013-04-02
Yohimbine to Enhance Cognitive Behavioral Therapy (CBT) for Social Anxiety
Group Cognitive Behavioral Therapy, Yohimbine Hydrochloride, Sugar Pill - Social Anxiety Disorder
Phase 3CompletedSouthern Methodist University402009-03-012013-11-11
Flushing in Social Anxiety Disorder on Seroquel
Seroquel, Sugar Pill - Social Anxiety Disorder
Phase 3CompletedSTART Clinic for Mood and Anxiety Disorders212008-10-012014-02-25
A Systems Level Intervention for Unemployed Persons With Social Anxiety Disorder
Cognitive Behavioral Therapy Group, Vocational Services as Usual - Social Anxiety Disorder
Phase 2 / Phase 3CompletedUniversity of Michigan1652008-04-012012-07-31
Treatment of Social Phobia and Panic Disorder in Adults
individual cognitive-behavioural therapy, stepped care model - Social Phobia, Panic Disorder
Phase 3CompletedHaukeland University Hospital1742008-03-012016-01-26
Effect of D-cycloserine Plus Cognitive Behavioral Therapy on People With Social Phobia
D-cycloserine, Cognitive behavioral therapy (CBT), Placebo - Social Anxiety Disorder
Phase 3CompletedBoston University Charles River Campus1692007-12-012019-02-26
A Comparison Between Internet Therapy and Group Therapy for Social Phobia - A Trial Using Cognitive Behavioural Therapy
CBT via the Internet, CBT group therapy - Social Phobia
Phase 3CompletedKarolinska Institutet1282007-11-012010-10-26
A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder
Namenda/Memantine - General Anxiety Disorder, Social Anxiety Disorder
Phase 3CompletedState University of New York - Upstate Medical University152006-12-012014-12-10
Social Anxiety Disorder Study Of Paroxetine
Paroxetine hydrochloride hydrate - Social Phobia
Phase 3CompletedGlaxoSmithKline3902005-12-012013-04-15
Long-term Study Of Paroxetine in Women and Men
BRL29060A, paroxetine hydrochloride hydrate - Social Phobia
Phase 3CompletedGlaxoSmithKline502005-10-012013-04-15
Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome
Duloxetine, Placebo - Anxiety Disorder
Phase 3CompletedMassachusetts General Hospital282004-06-012014-06-10
Quetiapine in Social Anxiety Disorder
quetiapine - Social Anxiety Disorder
Phase 2 / Phase 3CompletedDuke University152004-03-012006-12-19
Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder
Paroxetine, Cognitive behavioral therapy (CBT) - Social Anxiety Disorder
Phase 3CompletedTemple University1502003-12-012017-06-14
Child and Adolescent Anxiety Disorders (CAMS)
Sertraline (SRT), Cognitive Behavioral Therapy (CBT), Placebo - Anxiety Disorders, Social Phobia
Phase 3CompletedJohns Hopkins University4882003-01-012017-09-19

Showing 20 of 25. Sign in to see all of them.

Narrower conditions

Anxiety Disorders (11)  ·  Generalized Anxiety Disorder (7)  ·  Anxiety, Separation (4)  ·  Disease (2)  ·  Obsessive-Compulsive Disorder (2)  ·  Phobic Disorders (2)  ·  Asperger Syndrome (1)  ·  Attention Deficit Disorder with Hyperactivity (1)  ·  Autistic Disorder (1)  ·  Mutism (1)  ·  Panic Disorder (1)  ·  Psychological Well-Being (1)

Broader conditions

Mental Disorders (25)  ·  Phobic Disorders (23)  ·  Anxiety Disorders (14)  ·  Neurodevelopmental Disorders (6)  ·  Pathological Conditions, Signs and Symptoms (3)  ·  Pathologic Processes (2)  ·  Attention Deficit and Disruptive Behavior Disorders (1)  ·  Autism Spectrum Disorder (1)  ·  Behavior (1)  ·  Child Development Disorders, Pervasive (1)  ·  Communication Disorders (1)  ·  Language Disorders (1)  ·  Nervous System Diseases (1)  ·  Neurobehavioral Manifestations (1)  ·  Neurologic Manifestations (1)

Interventions

Cognitive Behavioral Therapy (5)  ·  Sugars (3)  ·  Quetiapine Fumarate (2)  ·  Therapeutics (2)  ·  Counseling (1)  ·  Cycloserine (1)  ·  Duloxetine Hydrochloride (1)  ·  Fluoxetine (1)  ·  Fluvoxamine (1)  ·  Hypericum extract LI 160 (1)  ·  Memantine (1)  ·  Paroxetine (1)  ·  Psychotherapy (1)  ·  Sertraline (1)  ·  Yohimbine (1)

Sponsors

GlaxoSmithKline (2)  ·  University of South Florida (2)  ·  Bionomics Limited (1)  ·  Boston University Charles River Campus (1)  ·  Duke University (1)  ·  Haukeland University Hospital (1)  ·  Johns Hopkins University (1)  ·  Karolinska Institutet (1)  ·  Massachusetts General Hospital (1)  ·  Modum Bad (1)  ·  National Center for Complementary and Integrative Health (NCCIH) (1)  ·  National Institute of Mental Health (NIMH) (1)  ·  Otsuka Pharmaceutical Development & Commercialization, Inc. (1)  ·  Pherin Pharmaceuticals, Inc. (1)  ·  START Clinic for Mood and Anxiety Disorders (1)

Countries

United States (16)  ·  Japan (2)  ·  Norway (2)  ·  Canada (1)  ·  Puerto Rico (1)  ·  Sweden (1)

Top investigators

Eric A Storch, Ph.D. (2)  ·  Asle Hoffart, Dr Psychol (1)  ·  Finn-Magnus Borge, Cand Psychol (1)  ·  Jasper A. Smits, PhD (1)  ·  Jasper Smits, Ph.D. (1)  ·  Jonathan Davidson, M.D. (1)  ·  Joseph Himle, PhD (1)  ·  Laurence Greenhill, MD (1)  ·  Mark H. Pollack, MD (1)  ·  Mark Riddle, MD (1)  ·  Martin A Katzman, MD (1)  ·  Michael H. Bloch, MD, MS (1)  ·  Michael Liebowitz (1)

Results publications

PMID 18030084, PMID 18974308, PMID 20013046, PMID 20051130, PMID 20206470, PMID 21391024, PMID 21483704, PMID 22122292, PMID 22320999, PMID 23357440, PMID 24129543, PMID 24237691, PMID 24260145, PMID 24417601, PMID 24477837, PMID 24565357, PMID 24610431, PMID 25461793, PMID 25721183, PMID 26081010, PMID 26366886, PMID 26708332, PMID 27561175, PMID 28735699, PMID 28956620, PMID 29877727, PMID 29960692, PMID 30906874, PMID 31471911, PMID 33705168, PMID 36479955, PMID 37861988, PMID 38217328, PMID 41773906

NIH funding

R01MH053703 (1), R01MH064481 (1), R01MH064726 (1), R01MH075889 (1), R01MH078308 (1), U01MH064089 (1)